Unless you are depressed:
"Novel aminopropiophenones as potential antidepressants. Foley, Kevin F.; Cozzi, Nicholas V. Department of Pharmacology and Toxicology, Brody School of Medicine, East Carolina University, Greenville, NC, USA. Drug Development Research (2003), 60(4), 252-260. Publisher: Wiley-Liss, Inc., CODEN: DDREDK ISSN: 0272-4391. Journal written in English. CAN 140:297283 AN 2003:954697 CAPLUS
Abstract
The atypical antidepressant drug bupropion and the psychostimulant drug methcathinone are both members of a chem. class known as aminopropiophenones. Differences in the psychoactive effects of these two drugs result from small variations in their chem. structures, but the relationship between chem. structure and psychoactivity has not been characterized. To investigate how structural modifications to aminopropiophenones affect antidepressant or stimulant activity, we synthesized several analogs of bupropion and methcathinone and tested the new compds. for antidepressant-like or psychostimulant effects. The synthesized compds. are 2-(methylamino)-1-(3-bromophenyl)propan-1-one (3-BMAP), 2-(methylamino)-1-(4-bromophenyl)propan-1-one (4-BMAP), 2-(iso-propylamino)-1-phenylpropan-1-one (i-PAP), and 2-(tert-butylamino)-1-phenylpropan-1-one (t-BAP). Bupropion, methcathinone, desipramine, and the newly-synthesized aminopropiophenones were administered to rats for behavioral testing. We used the Porsolt swim test to assess antidepressant-like activity and a locomotor activity assay to test for psychostimulant effects. All of the compds. displayed antidepressant-like effects in the Porsolt swim test. Some compds., including bupropion, increased locomotor activity at moderate-to-high doses. A halogenated analog of methcathinone, 4-BMAP, increased swim time but did not stimulate locomotor activity, even at the highest dose tested. The data indicate that Ph ring substitution or branched alkylamines can shift the psychopharmacol. profile of aminopropiophenones from stimulant activity to antidepressant-like activity. Several of the new drugs may be effective antidepressants in humans with fewer stimulant-like side effects compared to bupropion. "